We are live on ! Find out more
RPRX icon

Royalty Pharma
RPRX

487 hedge funds and large institutions have $11.6B invested in Royalty Pharma in 2025 Q3 according to their latest regulatory filings, with 92 funds opening new positions, 206 increasing their positions, 131 reducing their positions, and 53 closing their positions.

New
Increased
Maintained
Reduced
Closed

440% more call options, than puts

Call options by funds: $50.3M | Put options by funds: $9.31M

74% more first-time investments, than exits

New positions opened: 92 | Existing positions closed: 53

67% more funds holding in top 10

Funds holding in top 10: 6 → 10 (+4)

57% more repeat investments, than reductions

Existing positions increased: 206 | Existing positions reduced: 131

7% more funds holding

Funds holding: 455 → 487 (+32)

5.29% less ownership

Funds ownership: 81.34% → 76.05% (-5.3%)

6% less capital invested

Capital invested by funds: $12.4B → $11.6B (-$760M)

Holders
487
Holders Change
+32
Holders Change %
+7.03%
% of All Funds
6.39%
Holding in Top 10
10
Holding in Top 10 Change
+4
Holding in Top 10 Change %
+66.67%
% of All Funds
0.13%
New
92
Increased
206
Reduced
131
Closed
53
Calls
$50.3M
Puts
$9.31M
Net Calls
+$41M
Net Calls Change
-$22.7M

Top Buyers

1
Adage Capital Partners
Adage Capital Partners
Massachusetts
+$216M
2
Capital International Investors
Capital International Investors
California
+$193M
3
Jane Street
Jane Street
New York
+$86.6M
4
DAM
Dorsey Asset Management
Illinois
+$85.1M
5
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT)
United Kingdom
+$79.1M

Top Sellers

1
Vanguard Group
Vanguard Group
Pennsylvania
-$921M
2
Fidelity Investments
Fidelity Investments
Massachusetts
-$448M
3
Viking Global Investors
Viking Global Investors
Connecticut
-$93.6M
4
JAM
Jupiter Asset Management
United Kingdom
-$89M
5
Morgan Stanley
Morgan Stanley
New York
-$88.3M
Name Holding Trade Value Shares
Change 		Change in
Stake
Dimensional Fund Advisors
26
Dimensional Fund Advisors
Texas
$74.1M +$7.44M +205,498 +11%
AQR Capital Management
27
AQR Capital Management
Connecticut
$69.2M +$8.14M +224,811 +13%
Deutsche Bank
28
Deutsche Bank
Germany
$68.3M +$6.7M +185,196 +11%
HA
29
Homestead Advisers
Virginia
$67.1M -$1.34M -37,000 -2%
JP Morgan Chase
30
JP Morgan Chase
New York
$62.1M +$12.5M +346,108 +24%
CCMG
31
Clark Capital Management Group
Pennsylvania
$61.8M +$63.4M +1,751,842 New
Goldman Sachs
32
Goldman Sachs
New York
$58.1M +$45.6M +1,259,758 +326%
Invesco
33
Invesco
Georgia
$56.1M +$1.09M +30,138 +2%
UBS Group
34
UBS Group
Switzerland
$54.4M -$24.1M -665,167 -30%
Mitsubishi UFJ Trust & Banking
35
Mitsubishi UFJ Trust & Banking
Japan
$53.6M -$7.2M -198,889 -12%
BGIM
36
Brandywine Global Investment Management
Pennsylvania
$53.5M +$9.27M +256,116 +20%
GA
37
General Atlantic
New York
$52.9M – – –
Marshall Wace
38
Marshall Wace
United Kingdom
$52.3M +$53.7M +1,483,676 New
Raymond James Financial
39
Raymond James Financial
Florida
$51.2M +$11.8M +326,615 +29%
RP
40
Regal Partners
Australia
$50.6M +$3.26M +89,930 +7%
Russell Investments Group
41
Russell Investments Group
United Kingdom
$49.6M +$3.57M +98,649 +8%
Bank of New York Mellon
42
Bank of New York Mellon
New York
$44.9M -$1.82M -50,354 -4%
Robeco Institutional Asset Management
43
Robeco Institutional Asset Management
Netherlands
$44.1M +$17.2M +474,459 +61%
California Public Employees Retirement System
44
California Public Employees Retirement System
California
$43.2M -$8.33M -230,082 -16%
WCM
45
Wedge Capital Management
North Carolina
$42.1M -$814K -22,480 -2%
Two Sigma Investments
46
Two Sigma Investments
New York
$41.8M +$40.9M +1,130,209 +2,089%
Sumitomo Mitsui Trust Group
47
Sumitomo Mitsui Trust Group
Japan
$38.9M +$7.51M +207,338 +23%
Swiss National Bank
48
Swiss National Bank
Switzerland
$38.6M -$796K -22,000 -2%
T. Rowe Price Associates
49
T. Rowe Price Associates
Maryland
$36.4M +$27.3M +753,595 +272%
Los Angeles Capital Management
50
Los Angeles Capital Management
California
$35.9M +$25.3M +699,991 +221%
1
2
3 4 5

RPRX Hedge Fund Activity: Q3 2025 in Review

487 of the 7,619 institutional investors tracked by Wall St. Rank reported a position in Royalty Pharma (RPRX) for Q3 2025, worth a combined $11.6B — down 6.2% from $12.4B a quarter earlier.

Buyers outnumbered sellers: 92 funds opened new RPRX positions and 53 closed out — a net gain of 39 holders — while 206 added to existing stakes and 131 trimmed.

The largest buyer was Adage Capital Partners, adding an estimated $216M. The largest seller was Vanguard Group, cutting an estimated $921M.

  • 487 institutional investors held Royalty Pharma (RPRX) as of Q3 2025, up from 455 in Q2 2025.
  • Funds reported $11.6B of Royalty Pharma stock for Q3 2025, down 6.2% quarter-over-quarter.
  • 92 funds opened new Royalty Pharma positions in Q3 2025 and 53 closed out, a net change of +39 holders.
  • The largest Royalty Pharma buyer in Q3 2025 was Adage Capital Partners, an estimated $216M added.
  • The largest Royalty Pharma seller in Q3 2025 was Vanguard Group, an estimated $921M sold.

Based on aggregated 13F filings for Q3 2025.